Dry syrup formulation for reconstitution, for treating sickle cell disease in pediatric patients, comprises hydroxyurea and excipients
	SANJEEV J
	2023-09-27
专利权人	AKUMS DRUGS & PHARM LTD (AKUM-Non-standard)
申请日期	2023-09-27
专利号	IN202311065089-A
成果简介	NOVELTY - Dry syrup formulation for reconstitution comprises 50-80 wt.% hydroxyurea and excipients. USE - Dry syrup formulation for reconstitution for treating sickle cell disease in pediatric patients. No biological data given. ADVANTAGE - The formulation has high patient compliance, high shelf-life of more than 15 days, is stable at room temperature, suitable for pediatric patients who have difficulty in swallowing tablet and capsule, easy to manufacture and economical. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for reconstituting a dry powder formulation, which involves (a) providing a dry syrup formulation comprising 63.50 wt.% Hydroxyurea as active ingredient and; 1.04 wt.% sodium benzoate as preservative and; 2.50 wt.% sodium carboxymethyl cellulose as viscosity agent and; 1.67 wt.% sucralose as artificial sweetening agent and; v. 2.08 wt.% colloidal silicon dioxide as dispersing agent and; 24.00 wt.% mannitol as bulk sweetener and; 1.04 wt.% sodium bicarbonate as pH modifier; (b) combing the dry powder formulation with a solvent to reconstitute the dry powder hydroxyurea formulation into a liquid hydroxyurea formulation, where the reconstituted solution has shelf life of more than 15 days when stored at room temperature.
IPC 分类号	A61K-031/17 ; A61K-047/02 ; A61K-047/26 ; A61K-047/44 ; A61K-047/46 ; A61K-009/10 ; A61P-035/02 ; C07C-275/64
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20210
专题	中国科学院新疆生态与地理研究所
作者单位	AKUMS DRUGS & PHARM LTD (AKUM-Non-standard)
推荐引用方式 GB/T 7714	SANJEEV J. Dry syrup formulation for reconstitution, for treating sickle cell disease in pediatric patients, comprises hydroxyurea and excipients. IN202311065089-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。